|

AU-007 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Aulos Bioscience, Inc.1

Indications

  • Diabetes1
  • Cutaneous Melanoma1
  • Metastatic Cancer1
  • Advanced Solid Tumor1
  • Lung Cancer1

Miami, Florida1 trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Sylvester Comprehensive Cancer Center - Miami

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.